Novo Nordisk - Buy the Settlement: Hims & Hers Deal Reopens Growth Optionality
Novo Nordisk traded near the low end of its range after a difficult 2025. The recent Hims & Hers agreement and resolution of litigation removes an uncertainty and creates a modest new distribution channel for Wegovy/Ozempic. At a market cap of roughly $172.4B and a P/E near 11, the stock offers asymmetric upside over the next 45 trading days if mom…